Literature DB >> 10857995

Chemotherapy in non-small cell lung cancer.

C J Sweeney1, A B Sandler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10857995     DOI： 10.1023/a:1006330030333

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  97 in total

1.  Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer.

Authors:  C P Belani; C M Kearns; E G Zuhowski; K Erkmen; D Hiponia; D Zacharski; C Engstrom; R K Ramanathan; M J Capozzoli; J Aisner; M J Egorin
Journal:  J Clin Oncol       Date:  1999-02       Impact factor: 44.544

2.  Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer.

Authors:  V A Miller; K K Ng; S C Grant; H Kindler; B Pizzo; R T Heelan; R von Roemeling; M G Kris
Journal:  Ann Oncol       Date:  1997-12       Impact factor: 32.976

3.  Cancer statistics, 1998.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1998 Jan-Feb       Impact factor: 508.702

4.  Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer.

Authors:  T Le Chevalier; A Monnier; J Y Douillard; P Ruffie; X S Sun; L Belli; N Ibrahim; N Bougon; J Bérille
Journal:  Eur J Cancer       Date:  1998-12       Impact factor: 9.162

5.  Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study.

Authors:  U Gatzemeier; F A Shepherd; T Le Chevalier; P Weynants; B Cottier; H J Groen; R Rosso; K Mattson; H Cortes-Funes; M Tonato; R L Burkes; M Gottfried; M Voi
Journal:  Eur J Cancer       Date:  1996-02       Impact factor: 9.162

6.  cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.

Authors:  F M Schabel; M W Trader; W R Laster; T H Corbett; D P Griswold
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

7.  Phase I-II study of vinorelbine (Navelbine) plus cisplatin in advanced non-small cell lung cancer.

Authors:  P Berthaud; T Le Chevalier; P Ruffie; P Baldeyrou; R Arriagada; F Besson; T Tursz
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

8.  Cisplatin, ifosfamide, and vinorelbine combination chemotherapy in stage III-IV non-small-cell lung cancer: a phase II study.

Authors:  F Rey; P Astoul; L Marqueste; J M Petite; C Boutin; J R Viallat
Journal:  Am J Clin Oncol       Date:  1998-10       Impact factor: 2.339

9.  Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells.

Authors:  R J Parker; M D Dabholkar; K B Lee; F Bostick-Bruton; E Reed
Journal:  J Natl Cancer Inst Monogr       Date:  1993

10.  Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)

Authors:  T Cerny; S Kaplan; N Pavlidis; P Schöffski; R Epelbaum; J van Meerbeek; J Wanders; H R Franklin; S Kaye
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640
View more
  1 in total

1.  PET/CT and brain MRI role in staging NSCLC: prospective assessment of the accuracy, reliability and cost-effectiveness.

Authors:  Vasiliki-Konstantina I Gkogkozotou; Ioannis C Gkiozos; Andriani G Charpidou; Elias A Kotteas; Paraskevi G Boura; Sophia N Tsagouli; Konstantinos N Syrigos
Journal:  Lung Cancer Manag       Date:  2018-05-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.